Onco Wiki / Biomarcador

MUM1/IRF4 IHC (Múltiplo mieloma oncogene 1)

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDBIO-MUM1-IHC
TipoBiomarcador
Alegais
IRF4 IHCFator de regulação do interferão 4MUM1 imuno-histoquímicaMUM1/IRF4 expressão de proteínas
Estadoreviewed 2026-05-05 | pending_clinical_signoff
DoençasNenhuma declaração
FontesSRC-NCCN-BCELL-2025

Fatos de biomarcadores

Tipo de biomarcadorprotein_expression_ihc
Detalhes da mutação{"gene_id_ncbi": 3662, "gene_symbol": "IRF4", "note": "IRF4/MUM1 is a transcription factor expressed in post-germinal center B-cells, plasma cells, T-cells (activated), and NK-cells. In DLBCL: MUM1 positivity (>30% of tumor cells) in the Hans algorithm Step 3 context indicates non-GCB/ABC subtype. Nuclear staining pattern.\n"}
Medição
MétodoIHC on FFPE biopsy. Anti-MUM1/IRF4 antibody (clone MUM1p). Nuclear staining. Cut-off: >30% positive tumor cell nuclei = MUM1 positive. Hans algorithm Step 3: when CD10 negative AND BCL6 positive — MUM1 determines final COO: MUM1 >30% → non-GCB; MUM1 ≤30% → GCB.
Biomarcadores relacionadosBIO-CD10-IHC BIO-BCL6-IHC BIO-DLBCL-COO-HANS BIO-CD30-IHC

Notas

MUM1/IRF4 IHC completes the Hans algorithm for DLBCL COO classification. The Hans algorithm has ~80% concordance with GEP (Lymph2Cx) for GCB/non-GCB classification. Non-GCB DLBCL (by Hans) has historically worse prognosis with R-CHOP and is the target of emerging combination therapies (e.g., lenalidomide + R-CHOP = R²-CHOP in the Phoenix trial — showed benefit in young/fit non-GCB, particularly non-GCB by COO). The Hans IHC panel (CD10, BCL6, MUM1) is recommended in all DLBCL where molecular COO profiling is not available.

Usado por

Biomarcador